Search engine for discovering works of Art, research articles, and books related to Art and Culture
Javascript must be enabled to continue!
Off-label intravitreal brolucizumab and bevacizumab for chronic central serous chorioretinopathy
View through CrossRef
AIM: To compare the intravitreal brolucizumab and bevacizumab injections for chronic central serous chorioretinopathy (cCSC).
METHODS: Patients with cCSC were classified into bevacizumab and brolucizumab group. The proportion of complete resolution of subretinal fluid (SRF), best-corrected visual acuity (BCVA), central macular thickness (CMT), and subfoveal choroidal thickness (SFCT) were compared between the two groups.
RESULTS: A total of 40 eyes from 40 patients with aged 34-59y were enrolled in the study. Twenty eyes in bevacizumab group (17 males) and 20 eyes (18 males) in brolucizumab group. Comparing the proportion of complete resolution of SRF, the brolucizumab group was statistically significantly higher than the bevacizumab group (P<0.05). In 1mo, CMT was significantly reduced in the brolucizumab group compared to the bevacizumab group (265±69 vs 319±70 μm; P=0.021). However, there was no significant difference in CMT between the two groups at 2 and 3mo (P>0.05).
CONCLUSION: Brolucizumab is anatomically and functionally superior to bevacizumab in the treatment of patients with cCSC.
Press of International Journal of Ophthalmology (IJO Press)
Title: Off-label intravitreal brolucizumab and bevacizumab for chronic central serous chorioretinopathy
Description:
AIM: To compare the intravitreal brolucizumab and bevacizumab injections for chronic central serous chorioretinopathy (cCSC).
METHODS: Patients with cCSC were classified into bevacizumab and brolucizumab group.
The proportion of complete resolution of subretinal fluid (SRF), best-corrected visual acuity (BCVA), central macular thickness (CMT), and subfoveal choroidal thickness (SFCT) were compared between the two groups.
RESULTS: A total of 40 eyes from 40 patients with aged 34-59y were enrolled in the study.
Twenty eyes in bevacizumab group (17 males) and 20 eyes (18 males) in brolucizumab group.
Comparing the proportion of complete resolution of SRF, the brolucizumab group was statistically significantly higher than the bevacizumab group (P<0.
05).
In 1mo, CMT was significantly reduced in the brolucizumab group compared to the bevacizumab group (265±69 vs 319±70 μm; P=0.
021).
However, there was no significant difference in CMT between the two groups at 2 and 3mo (P>0.
05).
CONCLUSION: Brolucizumab is anatomically and functionally superior to bevacizumab in the treatment of patients with cCSC.
Related Results
Effect of intravitreal bevacizumab injection in central serous chorioretinopathy
Effect of intravitreal bevacizumab injection in central serous chorioretinopathy
Abstract
Purpose
To investigate the effect of intravitreal bevacizumab injection on the type of central serous chorioreti...
Effects of Intravitreal Aflibercept in Patients with Central Serous Chorioretinopathy
Effects of Intravitreal Aflibercept in Patients with Central Serous Chorioretinopathy
Purpose: The purpose of this study is to assess the efficacy of intravitreal injection of Afliberceptin patients with chronic central serous chorioretinopathy (CSCR).
Study ...
Use of Intravitreal Bevacizumab Injection among Patients Undergoing Surgical Retinal Interventions at Tertiary Eye Hospital: A Descriptive Cross-sectional Study
Use of Intravitreal Bevacizumab Injection among Patients Undergoing Surgical Retinal Interventions at Tertiary Eye Hospital: A Descriptive Cross-sectional Study
Introduction: Intravitreal Bevacizumab injection has now become a routine procedure for retina specialists throughout the world. Easy availability of this monoclonal antibody molec...
Contrasting outcomes of intravitreal brolucizumab – A dual narrative
Contrasting outcomes of intravitreal brolucizumab – A dual narrative
Abstract
Intravitreal brolucizumab is currently being used in the treatment of neovascular age-related macular degeneration (nAMD), with promising results. However, it ha...
Neuritis optik idiopatik dengan penyerta central serous chorioretinopathy sebagai manifestasi chronic relapsing inflammatory optic neuropathy: Sebuah laporan kasus
Neuritis optik idiopatik dengan penyerta central serous chorioretinopathy sebagai manifestasi chronic relapsing inflammatory optic neuropathy: Sebuah laporan kasus
Introduction: Idiopathic optic neuritis is an optic neuropathy with characteristics of optic nerve dysfunction that can be caused by various disorders of the optic nerve, including...
Abstract 2099: Model-riven optimization of anti-angiogenics combined with chemotherapy: application to bevacizumab + pemetrexed/cisplatin doublet in NSCLC-bearing mice
Abstract 2099: Model-riven optimization of anti-angiogenics combined with chemotherapy: application to bevacizumab + pemetrexed/cisplatin doublet in NSCLC-bearing mice
Abstract
Bevacizumab-containing protocols are all based upon the concomitant administration of the drugs given in a row. Bevacizumab is expected to induce a transien...
Short-Term Morphofunctional Changes in Previously Treated Neovascular AMD Eyes Switched to Brolucizumab
Short-Term Morphofunctional Changes in Previously Treated Neovascular AMD Eyes Switched to Brolucizumab
The purpose of the study is to explore the morphofunctional fluctuations in eyes treated for neovascular AMD (nAMD) when treatment is switched from aflibercept or ranibizumab to br...
Refractory Serositis In Gorham-Stout Syndrome
Refractory Serositis In Gorham-Stout Syndrome
Abstract
Background: Gorham-Stout syndrome (GSS) is a rare disorder with various presentations and unpredictable prognoses. Previous understandings of GSS mainly focused on...